These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 21811175)

  • 1. Serum HE4 Profile During Primary Chemotherapy of Epithelial Ovarian Cancer.
    Hynninen J; Auranen A; Dean K; Lavonius M; Carpen O; Perheentupa A; Seppänen M; Grénman S
    Int J Gynecol Cancer; 2011 Dec; 21(9):1573-8. PubMed ID: 21811175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
    Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer.
    Plotti F; Scaletta G; Capriglione S; Montera R; Luvero D; Lopez S; Gatti A; De Cicco Nardone C; Terranova C; Angioli R
    Int J Gynecol Cancer; 2017 May; 27(4):696-702. PubMed ID: 28406844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer.
    Vallius T; Hynninen J; Auranen A; Carpén O; Matomäki J; Oksa S; Virtanen J; Grénman S
    Tumour Biol; 2014 Dec; 35(12):12389-95. PubMed ID: 25190018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
    Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
    Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
    Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study.
    Romagnolo C; Leon AE; Fabricio ASC; Taborelli M; Polesel J; Del Pup L; Steffan A; Cervo S; Ravaggi A; Zanotti L; Bandiera E; Odicino FE; Scattolo N; Squarcina E; Papadakis C; Maggino T; Gion M
    Gynecol Oncol; 2016 May; 141(2):303-311. PubMed ID: 26801941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer.
    Chen WT; Gao X; Han XD; Zheng H; Guo L; Lu RQ
    Asian Pac J Cancer Prev; 2014; 15(1):101-5. PubMed ID: 24528007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer.
    Son JH; Chang K; Kong TW; Paek J; Chang SJ; Ryu HS
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1294-1301. PubMed ID: 29683235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
    Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
    Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical study of a CT evaluation model combined with serum CA125 in predicting the treatment of newly diagnosed advanced epithelial ovarian cancer.
    Qin L; Huang H; Chen M; Liang Y; Wang H
    J Ovarian Res; 2018 Jun; 11(1):49. PubMed ID: 29914567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
    Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
    Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome.
    Sandri MT; Bottari F; Franchi D; Boveri S; Candiani M; Ronzoni S; Peiretti M; Radice D; Passerini R; Sideri M
    Gynecol Oncol; 2013 Feb; 128(2):233-8. PubMed ID: 23200911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass.
    Chan KK; Chen CA; Nam JH; Ochiai K; Wilailak S; Choon AT; Sabaratnam S; Hebbar S; Sickan J; Schodin BA; Sumpaico WW
    Gynecol Oncol; 2013 Feb; 128(2):239-44. PubMed ID: 23063998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages.
    Kotowicz B; Fuksiewicz M; Sobiczewski P; Spiewankiewicz B; Jonska-Gmyrek J; Skrzypczak M; Kowalska M
    Eur J Obstet Gynecol Reprod Biol; 2015 Nov; 194():141-6. PubMed ID: 26398337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
    Shen Y; Li L
    Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.
    Nassir M; Guan J; Luketina H; Siepmann T; Rohr I; Richter R; Castillo-Tong DC; Zeillinger R; Vergote I; Van Nieuwenhuysen E; Concin N; Marth C; Hall C; Mahner S; Woelber L; Sehouli J; Braicu EI
    Tumour Biol; 2016 Mar; 37(3):3009-16. PubMed ID: 26419591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer.
    Manganaro L; Michienzi S; Vinci V; Falzarano R; Saldari M; Granato T; Viggiani V; Frati L; Anastasi E
    Oncol Rep; 2013 Nov; 30(5):2481-7. PubMed ID: 23970060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-FDG-PET/CT can identify histopathological non-responders to platinum-based neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Vallius T; Peter A; Auranen A; Carpén O; Kemppainen J; Matomäki J; Oksa S; Roering P; Seppänen M; Grénman S; Hynninen J
    Gynecol Oncol; 2016 Jan; 140(1):29-35. PubMed ID: 26515076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy.
    Rodriguez N; Rauh-Hain JA; Shoni M; Berkowitz RS; Muto MG; Feltmate C; Schorge JO; Del Carmen MG; Matulonis UA; Horowitz NS
    Gynecol Oncol; 2012 May; 125(2):362-6. PubMed ID: 22333992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.